Science

As artificial intelligence and deep biology converge, DAiNA will help lead the shift toward truly individualized cancer care, redefining how a patient's disease is understood and treated

Fundamental Biology

Personalized cancer care begins with understanding - at the molecular level

Cancer is a highly complex and adaptive disease, shaped by a unique interplay of genetic and epigenetic changes that influence behavior at the proteomic level. Rather than a single disease, cancer represents a constellation of rare, patient-specific conditions, with each tumor functioning as its own biological system. This individuality arises from a range of molecular dysfunctions and post-translational modifications that drive both tumor progression and resistance to treatment.

DAiNA will integrate multi-omic data to anticipate resistance and guide precision therapies

Traditional genomic profiling alone often fails to capture the full spectrum of cancer's functional biology. Considering most targeted treatments act on proteins, not genes or transcripts, proteomic and phosphoproteomic analyses will be critical in identifying actionable targets. Tumor progression is driven by dysregulated protein signaling networks, which may not be evident through DNA or RNA sequencing alone. A comprehensive multi-omic approach, combining genetic, proteomic, and functional data, will be essential to fully characterize tumors and inform individualized therapeutic strategies.

Tumors adapt through Darwinian selection, developing into diverse sub-clonal populations that respond to environmental pressures, evade immune detection, and acquire resistance to therapies. This evolutionary process highlights the need for dynamic and adaptable combination treatment strategies that consider not only molecular complexity, but also for the tumor microenvironment.

DAiNA aims to decode tumor individuality to drive a new standard in personalized oncology

Recognizing cancer as a unique condition in each patient demands a shift from one-size-fits-all treatment to systems-level precision care. DAiNA aims to transform oncology by combining integrated molecular analysis, AI-powered interpretation, and emerging therapeutics to redefine how each tumor is understood and treated. This future-facing approach envisions a world where every patient receives a therapy as unique as their disease.

Our Approach

DAiNA's AI-powered platform is designed to not only treat cancer, but also to continuously learn from it, adapt to it, and respond with increasing intelligence

DAiNA is being developed to transform cancer care by combining artificial intelligence with high-resolution molecular profiling. The platform will interpret complex biological data to guide treatment decisions, aiming to make cancer management faster, smarter, and more precise for both patients and clinicians.

Decoding cancer from cell to system

By integrating multi-modal data—including genetic, transcriptomic, proteomic, and functional biomarkers—DAiNA will offer real-time, data-informed treatment recommendations. This approach is designed to overcome delays that may be caused by current testing methods and institutional bottlenecks such as lengthy turnaround times and complex tumor board reviews. DAiNA’s future technology shall also include an ex vivo tumor testing system, designed to evaluate how individual tumors respond to different treatments outside the body. This proprietary method will help refine and accelerate therapy selection by giving clinicians functional insight into what works—before treatment begins.

Key Strategies

Analyzing tumor behavior and predicting disease progression
Selecting treatments based on integrated molecular and pathological signatures
Assessing toxicity risks linked to therapy options
Evaluating risk profile for recurrence, familial, and secondary cancer risk, and related preventive interventions